Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (opens new window)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Źródło‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indeks‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (opens new window)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (opens new window)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Źródło‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indeks‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (opens new window)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (opens new window)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Źródło‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indeks‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (opens new window)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (opens new window)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Źródło‎: Blood 2003;102(4):1529-30.

Indeks‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (opens new window)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (opens new window)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Źródło‎: Transfusion 2007;47(10):1830-6.

Indeks‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (opens new window)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (opens new window)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Źródło‎: Iran J Blood Cancer 2009;1(4):147-50.

Indeks‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (opens new window)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (opens new window)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Źródło‎: Int J Hematol 2012;95(1):51-6.

Indeks‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (opens new window)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (opens new window)

Perrine SP.

Źródło‎: Pediatr Ann 2008;37(5):339-46.

Indeks‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (opens new window)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (opens new window)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Źródło‎: Sci Rep. 2022;12(1):2752.

Indeks‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (opens new window)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (opens new window)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Źródło‎: Haematologica 2004;89(10):1172-8.

Indeks‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (opens new window)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (opens new window)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Źródło‎: Arch Iran Med 2009;12(3):295-7.

Indeks‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (opens new window)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (opens new window)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Źródło‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indeks‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (opens new window)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (opens new window)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Źródło‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indeks‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (opens new window)

Fetal globin gene inducers: novel agents and new potential. (opens new window)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Źródło‎: Ann N Y Acad Sci 2010;1202:158-64.

Indeks‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (opens new window)